WO2024242158A1 - がん性疼痛予防又は治療用組成物 - Google Patents

がん性疼痛予防又は治療用組成物 Download PDF

Info

Publication number
WO2024242158A1
WO2024242158A1 PCT/JP2024/018940 JP2024018940W WO2024242158A1 WO 2024242158 A1 WO2024242158 A1 WO 2024242158A1 JP 2024018940 W JP2024018940 W JP 2024018940W WO 2024242158 A1 WO2024242158 A1 WO 2024242158A1
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
halogen atoms
group
pharma
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2024/018940
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
えり香 久保
睦朗 山村
昌一 島田
雪子 山本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maruishi Pharmaceutical Co Ltd
Original Assignee
Maruishi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maruishi Pharmaceutical Co Ltd filed Critical Maruishi Pharmaceutical Co Ltd
Priority to JP2025522445A priority Critical patent/JPWO2024242158A1/ja
Priority to AU2024275598A priority patent/AU2024275598A1/en
Priority to KR1020257041808A priority patent/KR20260016503A/ko
Priority to EP24811164.3A priority patent/EP4699608A1/en
Priority to CN202480031574.7A priority patent/CN121079089A/zh
Publication of WO2024242158A1 publication Critical patent/WO2024242158A1/ja
Priority to IL324153A priority patent/IL324153A/en
Priority to MX2025013810A priority patent/MX2025013810A/es
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the present invention relates to a composition for preventing or treating cancer pain.
  • Cancer is one of the three major diseases that are the leading causes of death in Japan. Cancer symptoms vary depending on the type and location of the cancer, but a typical symptom is cancer pain. It is said that cancer pain is present in 70-80% of all patients with advanced cancer.
  • Non-Patent Document 1 It is believed that relief from cancer pain is essential to improving the quality of life (QOL) of cancer patients.
  • analgesics are basically selected in the order of the WHO three-step analgesia ladder, with analgesics selected according to the level of pain. As you move up to the second and third steps, drug treatment becomes centered around opioids.
  • opioids are known to cause a variety of side effects, including dependence (psychological dependence, physical dependence), tolerance (analgesic tolerance), and somnolence.
  • Non-Patent Documents 2-7 It has been reported that most drugs, except for opioids, are ineffective against cancer pain after a single dose in animal models of cancer pain. It has been reported that the non-opioid analgesic pregabalin was effective in animal models of cancer pain, but it is known to have sedative effects such as dizziness, drowsiness, and loss of consciousness as side effects (Non-Patent Documents 2 and 8).
  • Non-Patent Document 9 describes the evaluation of pregabalin's effect on the central nervous system by evaluating the coordination and spontaneous motor activity of rats using the rotarod method and the Supermex method, and it is known that pregabalin suppresses central nervous function (inhibits coordination) at a dose lower than the dose that shows an analgesic effect (Table 2 in Non-Patent Document 9).
  • Patent Documents 1 and 2 disclose a pharmaceutical composition containing a serotonin 3 receptor agonist including compound A and a pharma- ceutical acceptable carrier for preventing or treating chronic pain.
  • chronic pain is defined as "pain that continues beyond the time expected to be required for healing, or pain associated with a progressive non-cancer disease” (Non-Patent Document 1). It is not known that the composition is effective against cancer pain.
  • the present invention aims to provide a drug for preventing or treating cancer pain.
  • a pharmaceutical composition for preventing or treating cancer pain comprising a compound represented by the following formula (I) or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable carrier: [Wherein, m is an integer from 1 to 4; R 1 is independently selected from the group consisting of a hydrogen atom, a halogen atom, a methyl group which may be substituted with 1 to 3 halogen atoms, a methoxy group which may be substituted with 1 to 3 halogen atoms, and a methylthio group which may be substituted with 1 to 3 halogen atoms.
  • a compound represented by formula (I) or a pharma- ceutical acceptable salt thereof wherein the compound represented by formula (I) or a pharma- ceutical acceptable salt thereof is represented by the following formula: or a pharma- ceutical acceptable salt thereof.
  • a preventive or therapeutic agent for cancer pain comprising a compound represented by the above formula (I) or a pharma- ceutical acceptable salt thereof (wherein m and R1 in formula (I) have the same meaning as any one of the above [1] to [4]).
  • a cancer pain threshold elevating agent comprising the compound represented by the above formula (I) or a pharma- ceutical acceptable salt thereof (wherein m and R1 in formula (I) have the same meaning as any one of the above [1] to [4]).
  • a method for preventing or treating cancer pain comprising administering to a human or a non-human animal an effective amount of a compound represented by the above formula (I) or a pharma- ceutical acceptable salt thereof (wherein m and R1 in formula (I) have the same meaning as any one of the above [1] to [4]).
  • a method for increasing the threshold of cancer pain comprising administering to a human or a non-human animal an effective amount of a compound represented by the above formula (I) or a pharma- ceutical acceptable salt thereof (wherein m and R1 in formula (I) have the same meaning as any one of the above [1] to [4]).
  • a compound represented by the above formula (I) or a pharma- ceutical acceptable salt thereof for use in increasing cancer pain threshold (wherein m and R1 in formula (I) have the same meanings as any one of the above [1] to [4]).
  • the present invention can provide a preventive or therapeutic drug for cancer pain.
  • the present invention can also provide a preventive or therapeutic drug for cancer pain that does not have the side effects seen with pregabalin administration (e.g., sedative effect, etc.) and/or the side effects seen with opioid administration (e.g., dependence (psychological dependence, physical dependence), tolerance (analgesic tolerance), somnolence, etc.).
  • the present invention also preferably exhibits a preventive or therapeutic effect for cancer pain that is comparable to that of morphine when administered in a single dose.
  • the present invention also preferably exhibits a preventive or therapeutic effect for cancer pain that is comparable to that of morphine when administered orally.
  • Figure 1 shows the results of measuring the pain threshold in cancer pain model rats.
  • the values show the mean ⁇ standard error (S.E.) (number of cases in each group: 8). ** indicates that there is a significant difference at a risk level of 1% between the control and compound A treatment groups when tested by the Dunnett method.
  • Figure 2 shows the evaluation results of the effects (side effects) of Compound A on the central nervous system based on the change in spontaneous locomotor activity of mice administered Compound A. The values shown are the mean ⁇ standard error (S.E.) (number of animals in each group: 8). When tested using the Dunnett method with a risk level of 5%, there was no statistical difference between the control and Compound A treatment groups.
  • Figure 3 shows the evaluation results of the effect (side effects) of Compound A on the central nervous system based on the change in coordinated movement ability of rats administered Compound A.
  • the values show the mean ⁇ standard error (S.E.) (number of animals in each group: 6).
  • S.E. standard error
  • R 1 is independently selected from the group consisting of a hydrogen atom, a halogen atom, a methyl group which may be substituted with 1 to 3 halogen atoms, a methoxy group which may be substituted with 1 to 3 halogen atoms, and a methylthio group which may be substituted with 1 to 3 halogen atoms.
  • Halogen atoms refer independently to any of a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom.
  • R 1 in the above general formula (I) is a methoxy group substituted with at least one or more (preferably 1 to 3) halogen atoms (e.g., fluorine, chlorine, bromine, or iodine atoms) at substitutable positions.
  • halogen atoms e.g., fluorine, chlorine, bromine, or iodine atoms
  • n is an integer from 1 to 4, preferably an integer from 1 to 3, more preferably an integer from 1 to 2, and even more preferably 1.
  • R 1 is independently selected from the group consisting of a hydrogen atom, a halogen atom, a methyl group which may be substituted with 1 to 3 halogen atoms, a methoxy group which may be substituted with 1 to 3 halogen atoms, and a methylthio group which may be substituted with 1 to 3 halogen atoms.
  • the halogen atom in R 1 is preferably a fluorine atom or a chlorine atom, and particularly preferably a chlorine atom.
  • methyl group in R 1 which may be substituted with 1 to 3 halogen atoms
  • a methyl group which may be substituted with 1 to 3 fluorine atoms is preferred, and a methyl group or a trifluoromethyl group is particularly preferred.
  • R 1 which may be substituted with 1 to 3 halogen atoms
  • a methoxy group which may be substituted with 1 to 3 fluorine atoms is preferred, and a methoxy group or a trifluoromethoxy group is particularly preferred.
  • methylthio group in R 1 which may be substituted with 1 to 3 halogen atoms
  • a methylthio group which may be substituted with 1 to 3 fluorine atoms is preferable, and a methylthio group or a trifluoromethylthio group is particularly preferable.
  • each R 1 is independently a halogen atom, and preferably, each R 1 is a chlorine atom.
  • n is 1. In another embodiment, R 1 is a halogen atom and m is 1.
  • the compound of formula (I) or a pharma- ceutically acceptable salt thereof has the following formula (I'): [0023]
  • the compound is represented by the following formula: [0024] wherein R 1 has the same meaning as defined above, or a pharma- ceutically acceptable salt thereof.
  • the compound of formula (I) has the following formula: (i.e., Compound A (compound name: 1-(6-chloropyridin-2-yl)piperidin-4-amine)).
  • the compound represented by the following formula (I) or a pharma- ceutically acceptable salt thereof can act as a serotonin 3 receptor agonist.
  • Pharmaceutically acceptable salts include acid addition salts, metal salts, base addition salts, and amino acid addition salts. Specific examples include acid addition salts such as hydrochloride, hydrobromide, hydroiodide, sulfate, nitrate, phosphate, formate, acetate, propionate, fumarate, oxalate, malonate, succinate, methanesulfonate, ethanesulfonate, benzenesulfonate, toluenesulfonate, maleate, dimaleate, lactate, malate, tartrate, citrate, and trifluoroacetate; metal salts such as lithium salt, potassium salt, calcium salt, magnesium salt, sodium salt, zinc salt, and aluminum salt; base addition salts such as ammonium salt, diethanolamine salt, ethylenediamine salt, triethanolamine salt, and triethylamine salt; and amino acid addition salts such as glycine, lysine, arginine, ornithine
  • the compound represented by formula (I) or a pharma- ceutically acceptable salt thereof in the present invention includes any of its intramolecular salts, adducts, solvates or hydrates, cocrystals, etc.
  • one or more of the compounds represented by formula (I) or pharma- ceutically acceptable salts thereof may be administered to a patient as is, but if necessary, the compounds represented by formula (I) or pharma-ceutically acceptable salts thereof may be mixed with a pharma-ceutically acceptable carrier and provided as a formulation in a form well known to those skilled in the art.
  • Such carriers include, but are not limited to, commonly used pharmaceutical carriers such as excipients, lubricants, binders, disintegrants, preservatives, pH adjusters, diluents, and absorption enhancers.
  • excipients include sugar derivatives such as mannitol and sorbitol, starch derivatives such as corn starch and potato starch, and cellulose derivatives such as crystalline cellulose.
  • Lubricants include metal stearates such as magnesium stearate, and talc.
  • Binders include hydroxypropyl cellulose, hydroxypropyl methylcellulose, and polyvinylpyrrolidone.
  • Disintegrants include cellulose derivatives such as carboxymethyl cellulose and calcium carboxymethyl cellulose.
  • Preservatives include paraoxybenzoic acid esters such as methylparaben and propylparaben, and alcohols such as chlorobutanol and benzyl alcohol.
  • pH adjusters include inorganic acids such as hydrochloric acid, sulfuric acid, and phosphoric acid, organic acids such as acetic acid, succinic acid, fumaric acid, and malic acid, and salts thereof.
  • Diluents include, for example, water for injection. These pharma- ceutically acceptable carriers can be used alone or in combination of two or more.
  • cancer pain in the present invention has the meaning commonly used in the technical field, and is not particularly limited, but may include all pain that occurs in cancer patients, including at least one selected from pain directly caused by the cancer itself (tumor invasion, growth, metastasis, etc.), pain caused by cancer treatment (postoperative pain, chronic postoperative pain, pain caused by neuropathies due to chemotherapy, etc.), pain related to cancer (lower back pain caused by prolonged bed rest, lymphedema, bedsores, etc.), and pain caused by diseases unrelated to cancer that occur in cancer patients (spondylosis deformans, migraines, etc.). Cancer pain may be continuous pain or breakthrough pain. Cancer pain may be pain that responds to opioids or pain that does not respond to opioids.
  • cancer pain is pain including at least pain directly caused by the cancer itself.
  • cancer pain includes at least pain directly caused by the cancer itself, and further includes at least one pain selected from pain caused by cancer treatment (postoperative pain, postoperative chronic pain, pain associated with neurological damage caused by chemotherapy, etc.), cancer-related pain (lower back pain associated with prolonged bed rest, lymphedema, bedsores, etc.), and pain caused by a disease unrelated to cancer that occurs in a cancer patient (spondylosis deformans, migraine, etc.).
  • prevention of pain includes preventing the onset of pain and delaying the onset of pain in subjects who are at risk of developing pain.
  • treatment of pain means reducing, mitigating, improving, or partially or completely eliminating pain, inhibiting the progression of severity, etc. in a subject suffering from pain.
  • An effective amount refers to the dosage of a compound or a pharma- ceutical acceptable salt thereof that is sufficient to achieve the purpose of such prevention or treatment.
  • an effective amount for example, the explanation of the dosage and number of administrations below may be referred to.
  • the pharmaceutical composition of the present invention comprises a compound represented by formula (I) or a pharma- ceutically acceptable salt thereof.
  • the definitions of m and R1 in formula (I) can be referred to above.
  • the pharmaceutical composition of the present invention comprises a compound represented by formula (I') or a pharma- ceutically acceptable salt thereof.
  • the definitions of m and R1 in formula (I') can be referred to above.
  • the pharmaceutical composition of the present invention comprises compound A.
  • the compound of the present invention represented by formula (I) has an asymmetric carbon atom in the molecule, it can exist as multiple stereoisomers (i.e., diastereoisomers, optical isomers) based on the asymmetric carbon atom, and the active ingredient of the present invention includes any one of these stereoisomers and any mixture thereof.
  • the compound represented by formula (I) or a pharma- ceutically acceptable salt thereof in the present invention includes compounds labeled with isotopes (e.g., 2H , 3H , 13C , 14C , 15N , 18F , 32P , 35S , 125I , etc.) and deuterium conversion compounds.
  • isotopes e.g., 2H , 3H , 13C , 14C , 15N , 18F , 32P , 35S , 125I , etc.
  • the formula (I) or a pharma- ceutical acceptable salt thereof in the present invention can be administered orally or parenterally after mixing with the above-mentioned carriers as necessary.
  • the oral or parenteral preparations include tablets (e.g., sugar-coated tablets, film-coated tablets, sublingual tablets, orally disintegrating tablets, buccal tablets, etc.), pills, powders, granules, capsules (e.g., soft capsules, microcapsules, etc.), troches, syrups, liquids, emulsions, suspensions, controlled-release preparations (e.g., immediate-release preparations, sustained-release preparations, sustained-release microcapsules, etc.), aerosols, films (e.g., orally disintegrating films, oral mucosal patch films, etc.), injections (e.g., subcutaneous injections, intravenous injections, intramuscular injections, intraperitoneal injections, etc.), drip infusions, transdermal preparations, ointments
  • Formula (I) or a pharma- ceutical acceptable salt thereof in the present invention is excellent in that it shows a preventive or therapeutic effect on cancer pain with a single oral administration.
  • the compound of the present invention represented by formula (I) or a pharma- ceutically acceptable salt thereof can be formulated into the above-mentioned dosage form and then administered to, for example, humans or non-human animals (e.g., rats, mice, rabbits, sheep, pigs, cows, cats, dogs, monkeys, etc.), preferably humans or non-human mammals, more preferably humans, and especially human patients.
  • humans or non-human animals e.g., rats, mice, rabbits, sheep, pigs, cows, cats, dogs, monkeys, etc.
  • the dosage and frequency of administration of the compound represented by formula (I) or a pharma- ceutical acceptable salt thereof in the present invention may vary appropriately depending on conditions such as the severity of cancer pain, the age, weight, and sex of the patient, the type of drug, the dosage form, and the administration route.
  • the active ingredient can be administered parenterally, for example, subcutaneously, intravenously, intraperitoneally, intramuscularly, rectally, etc., at about 0.1 to 10 mg/kg body weight, preferably about 0.3 to 10 mg/kg body weight, more preferably about 1 to 5 mg/kg body weight, and particularly preferably about 1 to 3 mg/kg body weight per administration, as the compound represented by formula (I).
  • the active ingredient can be administered orally at about 1 to 100 mg/kg body weight, preferably about 3 to 100 mg/kg body weight, more preferably about 10 to 50 mg/kg body weight, and particularly preferably about 10 to 30 mg/kg body weight per administration, as the compound represented by formula (I).
  • the active ingredient can be administered parenterally, for example, subcutaneously, intravenously, intraperitoneally, intramuscularly, rectally, etc., per day to an adult, at about 0.001 to 1 mg/kg body weight, preferably about 0.005 to 0.3 mg/kg body weight, and particularly preferably about 0.01 to 0.1 mg/kg body weight of the compound represented by formula (I) per administration.
  • the active ingredient can be administered orally, at about 0.01 to 10 mg/kg body weight, preferably about 0.05 to 3 mg/kg body weight, and particularly preferably about 0.1 to 1 mg/kg body weight of the compound represented by formula (I) per administration.
  • the dosage may be administered once or in divided doses per day, for example, 1 to 3 times, 1 to 2 times, or once per day.
  • the compound represented by formula (I) or a pharma- ceutically acceptable salt thereof is preferably administered alone, for example, compound A, but if necessary, two or more compounds represented by formula (I) may be administered in combination, and may also be administered in combination with other drugs, for example, other pain treatment agents.
  • other pain treatment agents include opioids, nonsteroidal anti-inflammatory drugs, pregabalin, fluvoxamine, and pharma- ceutically acceptable salts thereof.
  • opioids include strong opioids and weak opioids.
  • nonsteroidal anti-inflammatory drugs include aspirin, ethenzamide, diflunisal, loxonin, ibuprofen, diclofenac, ketoprofen, naproxen, piroxicam, and indomethacin.
  • each drug may be administered simultaneously, sequentially, or separately.
  • each drug may be formulated as a combination containing two or more drugs, or each drug may be formulated as a separate composition.
  • the compound represented by formula (I) or a pharma- ceutically acceptable salt thereof in the present invention may be a commercially available product, or may be produced according to a publicly known or per se known method.
  • the compound represented by formula (I) or a pharma-ceutically acceptable salt thereof may be produced by the method described in Patent Document 1 or 2.
  • Compound A may also be a commercially available product.
  • Whether the compound can be used to prevent or treat cancer pain can be evaluated, for example, by using a cancer pain model animal in a conventionally known test system appropriately selected from known methods, comparing a group administered with a compound represented by formula (I) of the present invention or a pharma- ceutically acceptable salt thereof with a group not administered with the compound, measuring the pain threshold (e.g., 1, 3, 6, and 24 hours after administration). Based on known statistical processing methods, it is preferable that there is a significant tendency or a significant difference between the two groups, and it is more preferable that there is a significant difference.
  • the compound represented by formula (I) of the present invention or a pharma-ceutically acceptable salt thereof can also be used as a threshold elevating agent for cancer pain (e.g., 1, 3, and 6 hours after administration).
  • a pharmaceutical composition or agent containing a compound represented by formula (I) or a pharma- ceutical acceptable salt thereof can be formulated by appropriately mixing a pharma- ceutical acceptable carrier and additives, as necessary, with a compound represented by formula (I) or a pharma- ceutical acceptable salt thereof, which is the active ingredient, according to a known method for manufacturing pharmaceutical preparations (e.g., a method described in the Japanese Pharmacopoeia, etc.).
  • the mixing ratio of additives may be appropriately set based on the range normally adopted in the pharmaceutical field.
  • the additives that can be mixed but examples include various additives such as colorants, flavorings, and fragrances.
  • the term "about” is used to include, for example, small deviations. These terms may refer to, for example, within ⁇ 10%, within ⁇ 5%, within ⁇ 2%, within ⁇ 1%, within ⁇ 0.5%, within ⁇ 0.2%, within ⁇ 0.1%, or within ⁇ 0.05%. Such ranges are inclusive of experimental error inherent in the standard method used to measure and/or quantify a given value or range.
  • the present invention includes various combinations of the above configurations within the technical scope of the present invention, as long as the effects of the present invention are achieved.
  • Experiment 1 Pain treatment effects of Compound A and existing drugs (Experimental method) MRMT-1 (rat breast cancer cells) 3 ⁇ 10 4 cells/20 ⁇ L/body were injected into the medullary cavity of the proximal tibia metaphysis of the right limb of 5-week-old female Crl:CD (SD) SPF rats (Charles River Laboratories Japan) to prepare a bone metastasis model (day 0).
  • the rats were divided into 4 groups of 8 rats each (control (distilled water (trade name: Otsuka Distilled Water) (manufactured by Otsuka Pharmaceutical Factory, Inc.) administered), 10 mg/kg Compound A administered, 30 mg/kg Compound A administered, and morphine administered), as shown in Table 1 below.
  • control distilled water (trade name: Otsuka Distilled Water) (manufactured by Otsuka Pharmaceutical Factory, Inc.) administered
  • 10 mg/kg Compound A administered 10 mg/kg Compound A administered, 30 mg/kg Compound A administered, and morphine administered
  • Table 1 Table 1 below.
  • each drug was orally or subcutaneously administered at a volume of 2 mL/kg, and the pain threshold (g) of the right footpad was measured under blinded conditions at 1, 3, 6, and 24 hours after administration using a Dynamic Plantar Aesthesiometer (37450, manufactured by Ugo Basile), and the average value of the area under the pain threshold-time curve AUC (g hr) up to 24 hours after administration for each group was calculated.
  • a Dynamic Plantar Aesthesiometer 37450, manufactured by Ugo Basile
  • Experiment 2 Evaluation of the effects (side effects) of Compound A on the central nervous system based on changes in spontaneous motor activity and coordination caused by Compound A (Experimental method) (1) Measurement of spontaneous motor activity Five to six week old male ICR/SPF mice (Japan SLC Co., Ltd.) were divided into five groups of eight mice each (control (administered distilled water (trade name: Otsuka Distilled Water) (manufactured by Otsuka Pharmaceutical Factory, Inc.)), two groups administered with 10 mg/kg compound A, and two groups administered with 30 mg/kg compound A) as shown in Table 2 below.
  • control administered distilled water (trade name: Otsuka Distilled Water) (manufactured by Otsuka Pharmaceutical Factory, Inc.)
  • the rats were divided into 3 groups of 6 rats each (control (distilled water (trade name: Otsuka Distilled Water) (manufactured by Otsuka Pharmaceutical Factory Co., Ltd.) administration group), 10 mg/kg compound A administration group, and 30 mg/kg compound A administration group).
  • Compound A or distilled water was orally administered at a volume of 10 mL/kg, and the rotarod residence time 1, 3, 6, and 24 hours after administration was measured under the test conditions of a rotation speed of 10 rotations/min and a cutoff of 180 seconds. The results are shown in FIG. 3.
  • composition of the present invention is useful as a pharmaceutical composition for preventing or treating cancer pain.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/JP2024/018940 2023-05-25 2024-05-23 がん性疼痛予防又は治療用組成物 Ceased WO2024242158A1 (ja)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2025522445A JPWO2024242158A1 (cg-RX-API-DMAC7.html) 2023-05-25 2024-05-23
AU2024275598A AU2024275598A1 (en) 2023-05-25 2024-05-23 Composition for preventing or treating cancer pain
KR1020257041808A KR20260016503A (ko) 2023-05-25 2024-05-23 암성 동통 예방 또는 치료용 조성물
EP24811164.3A EP4699608A1 (en) 2023-05-25 2024-05-23 Composition for preventing or treating cancer pain
CN202480031574.7A CN121079089A (zh) 2023-05-25 2024-05-23 用于预防或治疗癌性疼痛的组合物
IL324153A IL324153A (en) 2023-05-25 2025-10-22 Composition for preventing or treating cancer pain
MX2025013810A MX2025013810A (es) 2023-05-25 2025-11-19 Composicion para la prevencion o el tratamiento del dolor por cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2023-086153 2023-05-25
JP2023086153 2023-05-25

Publications (1)

Publication Number Publication Date
WO2024242158A1 true WO2024242158A1 (ja) 2024-11-28

Family

ID=93589461

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2024/018940 Ceased WO2024242158A1 (ja) 2023-05-25 2024-05-23 がん性疼痛予防又は治療用組成物

Country Status (9)

Country Link
EP (1) EP4699608A1 (cg-RX-API-DMAC7.html)
JP (1) JPWO2024242158A1 (cg-RX-API-DMAC7.html)
KR (1) KR20260016503A (cg-RX-API-DMAC7.html)
CN (1) CN121079089A (cg-RX-API-DMAC7.html)
AU (1) AU2024275598A1 (cg-RX-API-DMAC7.html)
IL (1) IL324153A (cg-RX-API-DMAC7.html)
MX (1) MX2025013810A (cg-RX-API-DMAC7.html)
TW (1) TW202508584A (cg-RX-API-DMAC7.html)
WO (1) WO2024242158A1 (cg-RX-API-DMAC7.html)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5636481A (en) 1979-06-21 1981-04-09 Clin Midy Aminopiperidine* its manufacture* intermediate and medicine
JPH07145166A (ja) 1991-03-27 1995-06-06 Sanofi Sa 4−アミノ−1−(2−ピリジル)ピペリジン誘導体の利用
WO2019004292A1 (ja) * 2017-06-28 2019-01-03 国立大学法人大阪大学 セロトニン3受容体アゴニストによる疼痛の治療

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5636481A (en) 1979-06-21 1981-04-09 Clin Midy Aminopiperidine* its manufacture* intermediate and medicine
JPH07145166A (ja) 1991-03-27 1995-06-06 Sanofi Sa 4−アミノ−1−(2−ピリジル)ピペリジン誘導体の利用
WO2019004292A1 (ja) * 2017-06-28 2019-01-03 国立大学法人大阪大学 セロトニン3受容体アゴニストによる疼痛の治療
JP7090344B2 (ja) 2017-06-28 2022-06-24 国立大学法人大阪大学 セロトニン3受容体アゴニストによる疼痛の治療

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
"Package insert of LYRICA", July 2022, VIATRIS INC.
IRYOYOMAYAKU TEKISEISHIYO GUIDANCE ISSUED BY COMPLIANCE AND NARCOTICS DIVISION IN PHARMACEUTICAL SAFETY AND ENVIRONMENTAL HEALTH BUREAU OF MINISTRY OF HEALTH, LABOUR AND WELFARE, April 2017 (2017-04-01)
JANETTE NALLELY CORONA-RAMOS ET AL.: "The effect of Gabapentin and Tramadol in Cancer Pain Induced by Glioma Cell in Rat Femur", DRUG DEVELOPMENT RESEARCH, vol. 78, 2017, pages 173 - 183
KAWAI, KIRIO ET AL.: "Nociplastic pain: Understanding nociplastic pain from a perspective of palliative medicine", PAIN CLINIC, XX, JP, vol. 43, no. 12, 1 December 2022 (2022-12-01), JP , pages 1349 - 1355, XP009559724, ISSN: 0388-4171 *
MOHAMMAD ZAFAR IMAM ET AL.: "Assessment of the anti-allodynic efficacy of a glycine transporter 2 inhibitor relative to pregabalin and duloxetine in a rat model of prostate cancer-induced bone pain", PHARMACOLOGICAL REPORTS, vol. 72, 26 July 2020 (2020-07-26), pages 1418 - 1425
MOHAMMED EL MOUEDDEN ET AL.: "Pharmacological evaluation of opioid and non-opioid analgesics in a murine bone cancer model of pain", PHARMACOLOGY, BIOCHEMISTRY AND BEHAVIOR, vol. 86, 12 January 2007 (2007-01-12), pages 458 - 467
NAKAMURA YUKIKO, SUMI TAKUYA, MITANI OSAMU, OKAMOTO TAKASHI, KUBO ERIKA, MASUI KUNIHARU, KONDO MAKOTO, KOYAMA YOSHIHISA, USUI NORI: "SR 57227A, a serotonin type-3 receptor agonist, as a candidate analgesic agent targeting nociplastic pain", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM NL, vol. 622, 1 September 2022 (2022-09-01), Amsterdam NL , pages 143 - 148, XP093242747, ISSN: 0006-291X, DOI: 10.1016/j.bbrc.2022.07.027 *
OSAMU SAITO ET AL.: "Analgesic effects of nonsteroidal antiinflammatory drugs, acetaminophen, and morphine in a mouse model of bone cancer pain", JOURNAL OF ANESTHESIA, vol. 19, 2005, pages 218 - 224
SIMENG MA ET AL.: "Amitriptyline influences the mechanical withdrawal threshold in bone cancer pain rats by regulating glutamate transporter GLAST", MOLECULAR PAIN, vol. 15, 2019, pages 1 - 12
TANSY DONOVAN-RODRIGUEZ ET AL.: "Gabapentin Normalizes Spinal Neuronal Responses That Correlate with Behavior in a Rat Model of Cancer-induced Bone Pain", ANESTHESIOLOGY, vol. 102, 2005, pages 132 - 140
YUTAKA KITANO ET AL., FOLIA PHARMACOLOGICA JAPONICA, vol. 154, 2019, pages 352 - 361

Also Published As

Publication number Publication date
TW202508584A (zh) 2025-03-01
EP4699608A1 (en) 2026-02-25
AU2024275598A1 (en) 2026-01-15
CN121079089A (zh) 2025-12-05
MX2025013810A (es) 2025-12-01
IL324153A (en) 2025-12-01
JPWO2024242158A1 (cg-RX-API-DMAC7.html) 2024-11-28
KR20260016503A (ko) 2026-02-03

Similar Documents

Publication Publication Date Title
US10952976B2 (en) Compositions and methods for treating respiratory depression with fenfluramine
JP5921539B2 (ja) 下肢静止不能症候群を治療する方法
CN102781436B (zh) 纤维肌痛综合征的治疗方法
EP2258353A2 (en) Dosage form containing oxycodone and naloxone
RU2554857C2 (ru) Терапевтическое или профилактическое средство для заболеваний желчных путей
KR20170131242A (ko) 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도
JP5251870B2 (ja) ジスキネジアの治療または予防剤
JPWO2002053153A1 (ja) 神経因性疼痛治療及び予防薬
EP4349341A1 (en) Pharmaceutical preparation for preventing or treating pulmonary fibrosis
EP2475361B1 (en) N-substituted benzenepropanamides for use in the treatment of pain and inflammation
WO2023201390A1 (en) Aqueous quetiapine solutions
CN117177772A (zh) 伴有饥饿素抵抗性的恶病质的治疗剂或预防剂
JPS59206309A (ja) 急発作障害の処置及びそれに有用な製薬組成物
EP2014288A1 (en) Combination of benzyl-4, 5-dihydro-1H-imidazole derivative and an opioid receptor ligand
KR20260016503A (ko) 암성 동통 예방 또는 치료용 조성물
WO2007040535A1 (en) Use of polyamine analogs for treatment and prevention of intestinal polyps
CA3289710A1 (en) Composition for preventing or treating cancer pain
JP7527662B2 (ja) ピモジドとメトトレキサートの医薬組成物、及びその使用
JP7090344B2 (ja) セロトニン3受容体アゴニストによる疼痛の治療
JP2023549394A (ja) 注意欠陥/多動性障害の新規な治療
CN115768430A (zh) 伴随代谢异常的疾病或综合征中的肌力下降症状的改善剂或预防剂
US20150352099A1 (en) Compositions and Methods of Reducing Sedation
KR20120065392A (ko) 만성 동통 치료제
JP2772814B2 (ja) 記憶障害改善剤
JP2005314313A (ja) 過敏性腸症候群を予防又は治療するための医薬

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24811164

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 324153

Country of ref document: IL

WWP Wipo information: published in national office

Ref document number: 324153

Country of ref document: IL

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112025022986

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2025522445

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2024811164

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2025/013810

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2024811164

Country of ref document: EP

Effective date: 20251117

ENP Entry into the national phase

Ref document number: 2024811164

Country of ref document: EP

Effective date: 20251117

WWP Wipo information: published in national office

Ref document number: MX/A/2025/013810

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2024811164

Country of ref document: EP

Effective date: 20251117

ENP Entry into the national phase

Ref document number: 2024811164

Country of ref document: EP

Effective date: 20251117

WWE Wipo information: entry into national phase

Ref document number: AU2024275598

Country of ref document: AU

Ref document number: 828185

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 828185

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2024811164

Country of ref document: EP

Effective date: 20251117

WWE Wipo information: entry into national phase

Ref document number: 2025137791

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2024811164

Country of ref document: EP

Effective date: 20251117

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2024811164

Country of ref document: EP

Effective date: 20251117

ENP Entry into the national phase

Ref document number: 2024811164

Country of ref document: EP

Effective date: 20251117

ENP Entry into the national phase

Ref document number: 2024275598

Country of ref document: AU

Date of ref document: 20240523

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2024811164

Country of ref document: EP

Effective date: 20251117

WWP Wipo information: published in national office

Ref document number: 2025137791

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2024811164

Country of ref document: EP